Jaclyn Ann Bennet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jaclyn Ann Bennet has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Laura Smeaton
Harvard T.H. Chan School of Public Health , Boston, MA
2 shared publications - Alan Landay
Department of Medicine, University of Texas Medical Branch , Galveston, Texas
1 shared publication Amy Kantor
Harvard T.H. Chan School of Public Health , Boston, MA
1 shared publication- Anchalee Avihingsanon
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research and Infectious Diseases Centre, Bangkok 10330, Thailand
1 shared publication Anna Zhukova
Unité Bioinformatique Evolutive, Hub Bioinformatique et Biostatistique, USR3756 (C3BI//DBC), Institut Pasteur and CNRS , 25-28 Rue du Dr Roux, 75015 Paris, France
1 shared publication- Benjamin Linas
Boston Medical Center, Boston, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 18 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e81-e89
A 48-week, Randomized Controlled Trial of Doravirine for Individuals with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391)
Background: Integrase inhibitors (INSTI) and tenofovir alafenamide (TAF) have been associated with greater weight gain compared to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and tenofovir disoproxil fumarate (TDF), but the effects of an antiretroviral regimen switch on weight are unclear. Methods: This 48-week, 3 parallel group, open-label, multicenter, randomized controlled trial (NCT04636437) in people with HIV and obesity on an INSTI (bictegravir, dolutegravir, or raltegravir) with TAF/emtricitabine (FTC) assessed whether switching to the NNRTI doravirine (DOR) with TAF/FTC or TDF/FTC results in weight loss or stabilization. Treatment effects were estimated using linear regression adjusted for sex, race, and entry weight. Results: Of 147 participants randomized, 145 initiated their assigned treatment. At entry, median age was 49 years; BMI was 34.9 kg/m2, and time on INSTI+TAF/FTC was 3.4 years; 49% were female and 53% Black. After 48 weeks, estimated mean change in weight was -0.47% (95% confidence interval [CI]: -2.09,1.14) for the DOR+TAF/FTC arm, -2.73% (-4.22, -1.23) for DOR+TDF/FTC, and -1.84% (-3.37, -0.30) for INSTI+TAF/FTC. Estimated mean difference in weight change at 48 weeks for DOR vs. INSTI (both with TAF/FTC) was 1.36 percentage points (97.5% CI: -1.20,3.92), and -0.89 percentage points (-3.34,1.57) for DOR+TDF/FTC vs. INSTI+TAF/FTC. There was no evidence of variation by sex or race, nor of treatment differences for changes in fasting lipids, insulin resistance, fat mass, or bone mineral density. Conclusions: In people with HIV and obesity, switching from an INSTI+TAF/FTC regimen to DOR/FTC with either TAF or TDF did not produce clinically meaningful differences in weight change or metabolic health after 48 weeks.
- 18 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e81-e89
Top Cited PapersOpen AccessA 48-week, Randomized Controlled Trial of Doravirine for Individuals with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391)
Background: Integrase inhibitors (INSTI) and tenofovir alafenamide (TAF) have been associated with greater weight gain compared to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and tenofovir disoproxil fumarate (TDF), but the effects of an antiretroviral regimen switch on weight are unclear. Methods: This 48-week, 3 parallel group, open-label, multicenter, randomized controlled trial (NCT04636437) in people with HIV and obesity on an INSTI (bictegravir, dolutegravir, or raltegravir) with TAF/emtricitabine (FTC) assessed whether switching to the NNRTI doravirine (DOR) with TAF/FTC or TDF/FTC results in weight loss or stabilization. Treatment effects were estimated using linear regression adjusted for sex, race, and entry weight. Results: Of 147 participants randomized, 145 initiated their assigned treatment. At entry, median age was 49 years; BMI was 34.9 kg/m2, and time on INSTI+TAF/FTC was 3.4 years; 49% were female and 53% Black. After 48 weeks, estimated mean change in weight was -0.47% (95% confidence interval [CI]: -2.09,1.14) for the DOR+TAF/FTC arm, -2.73% (-4.22, -1.23) for DOR+TDF/FTC, and -1.84% (-3.37, -0.30) for INSTI+TAF/FTC. Estimated mean difference in weight change at 48 weeks for DOR vs. INSTI (both with TAF/FTC) was 1.36 percentage points (97.5% CI: -1.20,3.92), and -0.89 percentage points (-3.34,1.57) for DOR+TDF/FTC vs. INSTI+TAF/FTC. There was no evidence of variation by sex or race, nor of treatment differences for changes in fasting lipids, insulin resistance, fat mass, or bone mineral density. Conclusions: In people with HIV and obesity, switching from an INSTI+TAF/FTC regimen to DOR/FTC with either TAF or TDF did not produce clinically meaningful differences in weight change or metabolic health after 48 weeks.
- 28 February 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (6) , 1683-1694
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life
Background Direct-acting antivirals (DAA) are highly effective for the management of HCV disease. This study aims to evaluate changes in health-related quality of life (HQoL) among people with HCV who were treated with DAAs using a minimal monitoring (MINMON) approach. Methods ACTG A5360 was a multicenter, international (Brazil, South Africa, Thailand, Uganda, and USA) trial to assess the feasibility and efficacy of MINMON approach in people with HCV. We measured HQoL using EQ-5D-3L at baseline, sustained virological evaluation visit, week 48 and week 72, and described using EQ-5D summary index (ranges:0-1) and visual analog scale (VAS) score (ranges 0-100). We used paired T-tests to evaluate the change in EQ-5D summary and multivariable linear regression for changes in VAS scores. Results Overall, 394 individuals were included; most did not have cirrhosis (360; 91%) or problematic alcohol use (278; 71%). We found HQoL improvements for participants from Brazil and Thailand, but not for the USA. Participants reported high rates of pain/discomfort and anxiety/depression, with decreases over time only for Brazil. Factors associated with larger improvements in VAS scores included: cirrhosis at baseline, and non-use or problematic use of other substances (apart from tobacco/marijuana) compared to non-problematic use. Conclusion We found HQoL improvements among people with HCV following DAA treatment with variability across countries. Our findings reinforce the importance of DAA treatment, especially among those with advanced HCV disease. Continuous mental health care including depression and substance use support should be offered to individuals after HCV treatment. Trial Registration Number NCT03512210 (22-Oct-2018) Plain English Summary Direct-acting antivirals are highly effective for the management of hepatitis C disease. Recent studies have shown that hepatitis C treatment with direct-acting antivirals has a positive impact on quality of life. However, no studies have assessed quality of life among individuals starting direct-acting antivirals treatment across multiple countries representing high-, middle- and low-income settings. In this study, we evaluated changes in health-related quality of life among people with hepatitis C who were treated with direct-acting antivirals using a simplified treatment delivery and offering minimal in-person monitoring. We found quality of life improvements among persons with hepatitis C after direct-acting antivirals treatment, with differences across countries. Although direct-acting antivirals treatment works well and should be available to all persons with hepatitis C, we found that participants with cirrhosis (liver damage) had higher improvements in quality of life, reinforcing the importance of starting treatment among people with advanced hepatitis C. We also found high rates of anxiety and depression, pointing to the importance of adding mental health care and support to infectious diseases services.
- 28 February 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (6) , 1683-1694
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life
Background Direct-acting antivirals (DAA) are highly effective for the management of HCV disease. This study aims to evaluate changes in health-related quality of life (HQoL) among people with HCV who were treated with DAAs using a minimal monitoring (MINMON) approach. Methods ACTG A5360 was a multicenter, international (Brazil, South Africa, Thailand, Uganda, and USA) trial to assess the feasibility and efficacy of MINMON approach in people with HCV. We measured HQoL using EQ-5D-3L at baseline, sustained virological evaluation visit, week 48 and week 72, and described using EQ-5D summary index (ranges:0-1) and visual analog scale (VAS) score (ranges 0-100). We used paired T-tests to evaluate the change in EQ-5D summary and multivariable linear regression for changes in VAS scores. Results Overall, 394 individuals were included; most did not have cirrhosis (360; 91%) or problematic alcohol use (278; 71%). We found HQoL improvements for participants from Brazil and Thailand, but not for the USA. Participants reported high rates of pain/discomfort and anxiety/depression, with decreases over time only for Brazil. Factors associated with larger improvements in VAS scores included: cirrhosis at baseline, and non-use or problematic use of other substances (apart from tobacco/marijuana) compared to non-problematic use. Conclusion We found HQoL improvements among people with HCV following DAA treatment with variability across countries. Our findings reinforce the importance of DAA treatment, especially among those with advanced HCV disease. Continuous mental health care including depression and substance use support should be offered to individuals after HCV treatment. Trial Registration Number NCT03512210 (22-Oct-2018) Plain English Summary Direct-acting antivirals are highly effective for the management of hepatitis C disease. Recent studies have shown that hepatitis C treatment with direct-acting antivirals has a positive impact on quality of life. However, no studies have assessed quality of life among individuals starting direct-acting antivirals treatment across multiple countries representing high-, middle- and low-income settings. In this study, we evaluated changes in health-related quality of life among people with hepatitis C who were treated with direct-acting antivirals using a simplified treatment delivery and offering minimal in-person monitoring. We found quality of life improvements among persons with hepatitis C after direct-acting antivirals treatment, with differences across countries. Although direct-acting antivirals treatment works well and should be available to all persons with hepatitis C, we found that participants with cirrhosis (liver damage) had higher improvements in quality of life, reinforcing the importance of starting treatment among people with advanced hepatitis C. We also found high rates of anxiety and depression, pointing to the importance of adding mental health care and support to infectious diseases services.
- Open Access
- 9 June 2021
- Published by Oxford University Press (OUP) in Virus Evolution
- Vol. 7 (2) , veab055
Phylogenetic analysis of HIV-1 shows frequent cross-country transmission and local population expansions
Understanding of pandemics depends on the characterization of pathogen collections from well-defined and demographically diverse cohorts. Since its emergence in Congo almost a century ago, Human Immunodeficiency Virus Type 1 (HIV-1) has geographically spread and genetically diversified into distinct viral subtypes. Phylogenetic analysis can be used to reconstruct the ancestry of the virus to better understand the origin and distribution of subtypes. We sequenced two 3.6-kb amplicons of HIV-1 genomes from 3,197 participants in a clinical trial with consistent and uniform sampling at sites across 35 countries and analyzed our data with another 2,632 genomes that comprehensively reflect the HIV-1 genetic diversity. We used maximum likelihood phylogenetic analysis coupled with geographical information to infer the state of ancestors. The majority of our sequenced genomes (n = 2,501) were either pure subtypes (A–D, F, and G) or CRF01_AE. The diversity and distribution of subtypes across geographical regions differed; USA showed the most homogenous subtype population, whereas African samples were most diverse. We delineated transmission of the four most prevalent subtypes in our dataset (A, B, C, and CRF01_AE), and our results suggest both continuous and frequent transmission of HIV-1 over country borders, as well as single transmission events being the seed of endemic population expansions. Overall, we show that coupling of genetic and geographical information of HIV-1 can be used to understand the origin and spread of pandemic pathogens.
- 9 June 2021
- Published by Oxford University Press (OUP) in Virus Evolution
- Vol. 7 (2) , veab055
Open AccessPhylogenetic analysis of HIV-1 shows frequent cross-country transmission and local population expansions
Understanding of pandemics depends on the characterization of pathogen collections from well-defined and demographically diverse cohorts. Since its emergence in Congo almost a century ago, Human Immunodeficiency Virus Type 1 (HIV-1) has geographically spread and genetically diversified into distinct viral subtypes. Phylogenetic analysis can be used to reconstruct the ancestry of the virus to better understand the origin and distribution of subtypes. We sequenced two 3.6-kb amplicons of HIV-1 genomes from 3,197 participants in a clinical trial with consistent and uniform sampling at sites across 35 countries and analyzed our data with another 2,632 genomes that comprehensively reflect the HIV-1 genetic diversity. We used maximum likelihood phylogenetic analysis coupled with geographical information to infer the state of ancestors. The majority of our sequenced genomes (n = 2,501) were either pure subtypes (A–D, F, and G) or CRF01_AE. The diversity and distribution of subtypes across geographical regions differed; USA showed the most homogenous subtype population, whereas African samples were most diverse. We delineated transmission of the four most prevalent subtypes in our dataset (A, B, C, and CRF01_AE), and our results suggest both continuous and frequent transmission of HIV-1 over country borders, as well as single transmission events being the seed of endemic population expansions. Overall, we show that coupling of genetic and geographical information of HIV-1 can be used to understand the origin and spread of pandemic pathogens.
- Open Access
- 10 December 2020
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 35 (1) , 4
An incidental finding of chronic lymphocytic leukaemia in a patient with pulmonary tuberculosis
In this case report, we described a 48-year-old human immunodeficiency virus-negative man with pulmonary tuberculosis (TB) who had an incidental finding of concurrent chronic lymphocytic leukaemia. We highlighted the importance of considering other differential diagnoses when patients present with TB or haematological malignancies. We also discussed the difficulties in diagnosis when both of these conditions co-exist and how this affected treatment and management.
- 10 December 2020
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 35 (1) , 4
Open AccessAn incidental finding of chronic lymphocytic leukaemia in a patient with pulmonary tuberculosis
In this case report, we described a 48-year-old human immunodeficiency virus-negative man with pulmonary tuberculosis (TB) who had an incidental finding of concurrent chronic lymphocytic leukaemia. We highlighted the importance of considering other differential diagnoses when patients present with TB or haematological malignancies. We also discussed the difficulties in diagnosis when both of these conditions co-exist and how this affected treatment and management.